Anthropic wants to use Claude AI to help discover new lifesaving drugs, says 'the best way to identify and work…
- Anthropic is expanding Claude's role across several stages of drug development
- Generate Biomedicines reports a 70% reduction in CAR T-cell component length
- Modified immune cells produced roughly ten times more cancer-detecting receptors
Anthropic is expanding Claude’s involvement in pharmaceutical research, working with biotechnology developers on projects intended to accelerate the creation of new medicines.
The AI company has laid out in a new blog post how it is examining scientific and administrative obstacles affecting drug development, from molecular design to clinical trial preparation.
Its collaborations involve potential treatments for cancer, food allergies and rare muscular disorders, although most of the treatments remain at experimental stages.
Claude enters drug development programmes
At Generate Biomedicines, six scientists used Claude Code to modify a component of CAR T-cell therapy, traditionally employed against blood cancers.
Their work sought to create additional room for genetic instructions that could help the treatment address solid tumours.
The...
Copyright of this story solely belongs to www.techradar.com. To see the full text click HERE
